ERYP

Erytech Pharma Share Price

5.90
-0.25 (-4.07%)
Upgrade to Real-Time
Afterhours (Closed)
5.90
Best deals to access real time data!
Big Cap Pro
Monthly Subscription
for only
$52.04
Small Cap Pro
Monthly Subscription
for only
$49.05
DDE w/Realtime (Monthly)
Monthly Subscription
for only
$34.10
VAT not included
Company Name Stock Ticker Symbol Market Type
Erytech Pharma SA ERYP NASDAQ Depository Receipt
  Price Change Change Percent Stock Price Last Traded
-0.25 -4.07% 5.90 19:56:22
Open Price Low Price High Price Close Price Prev Close
6.12 5.88 6.1208 5.90 6.15
Bid Price Ask Price Spread News
5.90 6.12 0.22 - -
Trades Volume VWAP Dollar Volume Avg Volume
251 36,565  6.02  220,236 -
Last Trade Time Type Quantity Stock Price Currency
17:57:13 40  5.88 USD

Period:

Draw Mode:

Erytech Pharma SA Financials

Market Cap Shares in Issue Float Revenue Profit/Loss EPS PE Ratio
 163.59M 27.73M 27.73M  -  - -4.83 -1.20
Short Interest Dividends Per Share Dividend Yield Ex-Div Date Insider B/S Insider % Owned
-  - - - -

more financials information »

News Erytech Pharma

Loading Messages....

{{bbMessage.M_Alias}} {{bbMessage.MSG_Date}} {{bbMessage.HowLongAgo}} {{bbMessage.MSG_ID}} {{bbMessage.MSG_Subject}}

Loading Messages....


No posts yet, be the first! No {{symbol}} Message Board. Create One! See More Posts on {{symbol}} Message Board See More Message Board Posts

ERYP Historical

Period Open High Low VWAP Avg. Daily Vol Change %
1 Week0.000.000.000.0000.000.0%
1 Month0.000.000.000.0000.000.0%
3 Months0.000.000.000.0000.000.0%
6 Months0.000.000.000.0000.000.0%
1 Year0.000.000.000.0000.000.0%
3 Years0.000.000.000.0000.000.0%
5 Years0.000.000.000.0000.000.0%

Erytech Pharma SA is a clinical-stage biopharmaceutical company developing innovative therapies for severe forms of cancer and orphan diseases. Its ERYCAPS platform, uses a novel technology to encapsulate therapeutic drug substances inside erythrocytes, or red blood cells, or RBC. It is developing a pipeline of product candidates for patients with high unmet medical needs. Its lead product candidate eryaspase, also referred as GRASPA, targets the metabolism of cancer cells by depriving the cells of asparagine, an amino acid necessary for their survival and critical in maintaining the cells' rapid growth rate.
Your Recent History
NASDAQ
ERYP
Erytech Ph..
Register now to watch these stocks streaming on the ADVFN Monitor.

Monitor lets you view up to 110 of your favourite stocks at once and is completely free to use.

By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions

P: V: D:20210923 00:24:40